Press Releases
& News
Barnik Invest Group is more than just an investment company.
Barnik Invest’s Portfolio Company, Cell4Cure, Forges Strategic Partnership with Bartlett Hill Partners to lead North American Business Development activities
Solna, Stockholm, Sweden – March 12, 2025 – Barnik Invest’s Portfolio Company, Cell4Cure AB, a pioneering Swedish biotech company developing innovative immune tolerance therapies, last week announced its strategic partnership with Bartlett Hill Partners LLC, a leading advanced therapies consulting group based in Boston, to spearhead its North American business development initiatives.
Barnik Invest Group Bolagizes Joint Venture with DynalisPharma, Creating BoniPharmex AB
Stockholm, Sweden – Barnik Invest Group today announced the bolagization of its joint venture project with DynalisPharma, resulting in the formation of BoniPharmex AB. This strategic move solidifies the partnership and positions BoniPharmex for significant growth in the market for probiotics and dietary supplements BoniPharmex was initially founded in 2021 as a
Barnik Invest Group Announces the Formation of Barnik Holdings AB
Stockholm, Sweden – Barnik Invest Group, an investment firm dedicated to pioneering the advancement of innovative life science companies in the Nordics, today announced the formation of Barnik Holdings AB. This new holding company will serve as the umbrella entity for all Barnik Invest Group portfolio companies. Barnik Holdings AB will offer
Barnik Invest Group Appoints Dr. Benedict Broennimann as Chief Scientific Officer
Stockholm, Sweden – Barnik Invest Group, today announced the appointment of Dr. Benedict Broennimann as Chief Scientific Officer. Dr. Broennimann is a highly accomplished medical and business executive with over 20 years of experience in the Life sciences industry. His extensive expertise and leadership will be invaluable as Barnik Invest Group continues
Barnik Invest Group to Showcase Portfolio Companies at Arab Health 2025
Stockholm, Sweden – Barnik Invest Group, today announced its participation in the 50th edition of Arab Health, taking place at the Dubai World Trade Centre from January 27-30, 2025. Barnik Invest Group will showcase its diverse portfolio of innovative companies at the event. Visitors to the Barnik Invest Group booth will have
BoniPharmex Achieves Nationwide Distribution of FilVel® Products in Sweden
Stockholm, Sweden – BoniPharmex, a joint venture between StartUpPharma Int. AB, a wholly-owned subsidiary of Barnik Invest Group, and DynalisPharma, today announced the successful nationwide distribution of its FilVel® product line across all major pharmacies in Sweden, including Apotek Hjärtat, Apoteket AB, Kronans Apotek, Doz Apotek, Apotea, MEDS Apotek, and Apohem. BoniPharmex
Barnik Invest Launches Cell4Cure AB to Advance Innovative Immunotherapy
Stockholm, Sweden – Barnik Invest Group is pleased to announce the official launch of Cell4Cure AB, a new company focused on developing advanced therapies based on antigen-specific dendritic cell mediated tolerance. This innovative approach aims to treat diseases where the immune system attacks the body’s own tissues. A consortium of former Idogen
BoniPharmex Launches Five New Products in the Swedish Market
Stockholm, Sweden – BoniPharmex, a joint venture between StartUpPharma Int. AB, a wholly-owned subsidiary of Barnik Invest Group, and DynalisPharma, today announced the launch of five new products in the Swedish market. These innovative dietary supplements, collectively known as the FilVel® Solar System, offer a holistic approach to health and well-being. The
